NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis $4.35 -0.02 (-0.46%) Closing price 04:00 PM EasternExtended Trading$4.39 +0.04 (+1.03%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AbCellera Biologics Stock (NASDAQ:ABCL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AbCellera Biologics alerts:Sign Up Key Stats Today's Range$4.32▼$4.5250-Day Range$3.33▼$5.1552-Week Range$1.89▼$5.82Volume2.15 million shsAverage Volume5.04 million shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company Overview AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Read More AbCellera Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreABCL MarketRank™: AbCellera Biologics scored higher than 43% of companies evaluated by MarketBeat, and ranked 657th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAbCellera Biologics has only been the subject of 4 research reports in the past 90 days.Read more about AbCellera Biologics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.59) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AbCellera Biologics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.76% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in AbCellera Biologics has recently increased by 11.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.76% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in AbCellera Biologics has recently increased by 11.45%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.94 News SentimentAbCellera Biologics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.Search InterestOnly 22 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows8 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders28.90% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbCellera Biologics' insider trading history. Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABCL Stock News HeadlinesAbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575August 27 at 9:35 AM | finance.yahoo.comTruist Financial Reiterates a Buy Rating on AbCellera Biologics (ABCL), Sets a $10 PTAugust 26 at 5:12 AM | msn.comThis stock could leave NVDA in the dustInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.August 27 at 2:00 AM | InvestorPlace (Ad)AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial ResultsAugust 17, 2025 | msn.comAbCellera Biologics (NASDAQ:ABCL) Upgraded by Wall Street Zen to Hold RatingAugust 17, 2025 | americanbankingnews.comTruist Financial Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)August 16, 2025 | theglobeandmail.comAbCellera to Participate at Upcoming Investor Conferences in SeptemberAugust 12, 2025 | businesswire.comIndustry Analysts Just Made A Huge Upgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) Revenue ForecastsAugust 12, 2025 | finance.yahoo.comSee More Headlines ABCL Stock Analysis - Frequently Asked Questions How have ABCL shares performed this year? AbCellera Biologics' stock was trading at $2.93 at the start of the year. Since then, ABCL shares have increased by 48.6% and is now trading at $4.3550. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) released its earnings results on Thursday, August, 7th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. The firm earned $17.08 million during the quarter, compared to analyst estimates of $7.55 million. AbCellera Biologics had a negative net margin of 511.88% and a negative trailing twelve-month return on equity of 16.17%. Read the conference call transcript. When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO. Who are AbCellera Biologics' major shareholders? AbCellera Biologics' top institutional shareholders include Orbimed Advisors LLC (1.12%), Norges Bank (0.21%), Lazard Asset Management LLC (0.17%) and Geode Capital Management LLC (0.12%). Insiders that own company stock include Holdings Ltd Thermopylae and Andrew Booth. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbCellera Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbCellera Biologics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), TotalEnergies (TTE) and AU Optronics (AUOTY). Company Calendar Last Earnings8/07/2025Today8/27/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABCL CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees500Year FoundedN/APrice Target and Rating Average Price Target for AbCellera Biologics$8.00 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+78.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$162.86 million Net Margins-511.88% Pretax Margin-604.66% Return on Equity-16.17% Return on Assets-12.24% Debt Debt-to-Equity RatioN/A Current Ratio11.07 Quick Ratio11.07 Sales & Book Value Annual Sales$28.83 million Price / Sales46.49 Cash FlowN/A Price / Cash FlowN/A Book Value$3.37 per share Price / Book1.33Miscellaneous Outstanding Shares298,830,000Free Float212,470,000Market Cap$1.34 billion OptionableOptionable Beta0.65 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ABCL) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.